Send to

Choose Destination
Vaccine. 2010 Jul 12;28(31):5023-30. doi: 10.1016/j.vaccine.2010.05.014. Epub 2010 May 21.

Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus.

Author information

Novartis Vaccines and Diagnostics, Via Fiorentina 1, Siena 53100, Italy.


Serum bactericidal activity using human complement is the basis for established correlates of protection against invasive meningococcal disease. During the development of multicomponent protein-based vaccines against meningococcus B, it is necessary to measure antigen-specific bactericidal responses. This is not straightforward because each strain may be killed by antibodies to multiple antigens. We characterized a large panel of strains and, using a competitive inhibition SBA, we identified four strains that are each specifically killed by bactericidal antibodies to one of the major vaccine components. These strains provide a straightforward approach to demonstrate protective responses to each component of the vaccine and demonstrate that each of the antigens in the vaccine is sufficient to provide a potentially protective level of bactericidal activity.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center